Literature DB >> 29097161

A behavioral and pharmacological characterization of palatable diet alternation in mice.

Catherine F Moore1, Gabrielle S Schlain2, Samantha Mancino2, Valentina Sabino2, Pietro Cottone3.   

Abstract

Obesity and eating disorders are widespread in Western societies. Both the increased availability of highly palatable foods and dieting are major risk factors contributing to the epidemic of disorders of feeding. The purpose of this study was to characterize an animal model of maladaptive feeding induced by intermittent access to a palatable diet alternation in mice. In this study, mice were either continuously provided with standard chow food (Chow/Chow), or provided with standard chow for 2days and a high-sucrose, palatable food for 1day (Chow/Palatable). Following stability of intake within the cycling paradigm, we then investigated the effects of several pharmacological treatments on excessive eating of palatable food: naltrexone, an opioid receptor antagonist, SR141716A, a cannabinoid-1 receptor antagonist/inverse agonist, and BD-1063, a sigma-1 receptor antagonist. Over successive cycles, Chow/Palatable mice showed an escalation of palatable food intake within the first hour of renewed access to palatable diet and displayed hypophagia upon its removal. Naltrexone, SR141716A, and BD-1063 all reduced overconsumption of palatable food during this first hour. Here we provide evidence of strong face and convergent validity in a palatable diet alternation model in mice, confirming multiple shared underlying mechanisms of pathological eating across species, and thus making it a useful therapeutic development tool.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BD-1063; Food intake; Naltrexone; Overeating; Palatable diet; SR141716A

Mesh:

Substances:

Year:  2017        PMID: 29097161      PMCID: PMC5911178          DOI: 10.1016/j.pbb.2017.10.013

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  74 in total

Review 1.  Pathological Overeating: Emerging Evidence for a Compulsivity Construct.

Authors:  Catherine F Moore; Valentina Sabino; George F Koob; Pietro Cottone
Journal:  Neuropsychopharmacology       Date:  2016-12-06       Impact factor: 7.853

2.  Activation of σ-receptors induces binge-like drinking in Sardinian alcohol-preferring rats.

Authors:  Valentina Sabino; Pietro Cottone; Angelo Blasio; Malliga R Iyer; Luca Steardo; Kenner C Rice; Bruno Conti; George F Koob; Eric P Zorrilla
Journal:  Neuropsychopharmacology       Date:  2011-02-23       Impact factor: 7.853

3.  Involvement of sigma (sigma) receptors in the acute actions of methamphetamine: receptor binding and behavioral studies.

Authors:  Emily C Nguyen; Kari A McCracken; Yun Liu; Buddy Pouw; Rae R Matsumoto
Journal:  Neuropharmacology       Date:  2005-10       Impact factor: 5.250

4.  Alcohol preferring (P) rats as a model for examining sex differences in alcohol use disorder and its treatment.

Authors:  Catherine F Moore; Wendy J Lynch
Journal:  Pharmacol Biochem Behav       Date:  2015-02-21       Impact factor: 3.533

5.  Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Neuroreport       Date:  2004-09-15       Impact factor: 1.837

6.  Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716).

Authors:  Caroline Cohen; Ghislaine Perrault; Guy Griebel; Philippe Soubrié
Journal:  Neuropsychopharmacology       Date:  2005-01       Impact factor: 7.853

7.  Baclofen, raclopride, and naltrexone differentially reduce solid fat emulsion intake under limited access conditions.

Authors:  R E Rao; F H E Wojnicki; J Coupland; S Ghosh; R L W Corwin
Journal:  Pharmacol Biochem Behav       Date:  2008-02-15       Impact factor: 3.533

8.  Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice.

Authors:  Frédérique Dol-Gleizes; Réjane Paumelle; Virgile Visentin; Anne-Marie Marés; Perrine Desitter; Nathalie Hennuyer; Andries Gilde; Bart Staels; Paul Schaeffer; Françoise Bono
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-10-09       Impact factor: 8.311

9.  Which foods may be addictive? The roles of processing, fat content, and glycemic load.

Authors:  Erica M Schulte; Nicole M Avena; Ashley N Gearhardt
Journal:  PLoS One       Date:  2015-02-18       Impact factor: 3.240

Review 10.  Dieting and restrained eating as prospective predictors of weight gain.

Authors:  Michael R Lowe; Sapna D Doshi; Shawn N Katterman; Emily H Feig
Journal:  Front Psychol       Date:  2013-09-02
View more
  3 in total

1.  Sigma-1 receptor ablation impedes adipocyte-like differentiation of mouse embryonic fibroblasts.

Authors:  Huan Yang; Hongtao Shen; Jing Li; Kristin I Stanford; Lian-Wang Guo
Journal:  Cell Signal       Date:  2020-08-02       Impact factor: 4.315

2.  The histamine H3 receptor inverse agonist pitolisant reduces body weight in obese mice.

Authors:  Magdalena Kotańska; Kamil J Kuder; Katarzyna Szczepańska; Jacek Sapa; Katarzyna Kieć-Kononowicz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-05-25       Impact factor: 3.000

3.  Antagonism of Sigma-1 receptor blocks heavy alcohol drinking and associated hyperalgesia in male mice.

Authors:  Sema G Quadir; Sean M Tanino; Yasmine N Sami; Margaret A Minnig; Malliga R Iyer; Kenner C Rice; Pietro Cottone; Valentina Sabino
Journal:  Alcohol Clin Exp Res       Date:  2021-07-05       Impact factor: 3.928

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.